Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas With Met Fusion Gene
Apollomics宣佈Vebreltinib在中國獲准作爲首創的具有Met Fusion基因的神經膠質瘤治療藥物
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas With Met Fusion Gene
Apollomics宣佈Vebreltinib在中國獲准作爲首創的具有Met Fusion基因的神經膠質瘤治療藥物
使用瀏覽器的分享功能,分享給你的好友吧